Drug intelligence / Profile preview

KINE-301A

Development stage: Preclinical
Lead developer: Kine Sciences
Modality: Peptides

Overview

KINE-301A is a preclinical-stage peptide therapeutic developed by Kine Science for the treatment of psoriasis. The drug functions as an immune modulator by specifically targeting Th17 cells, which are central to the inflammatory cascade in psoriatic lesions. By regulating the activity or differentiation of these T-helper cells, KINE-301A aims to suppress the overproduction of inflammatory cytokines that drive keratinocyte proliferation and skin inflammation. The asset is part of Kine Science's pipeline of 'Kine-Peptides' designed for targeted immune modulation.

Beyond the preview

Go deeper on KINE-301A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KINE-301A.

Explore the full profile